Selected research
Industry Research
Cell Therapy CDMO Industry Research Report 2026
Market perspective
The global Cell Therapy CDMO market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Cell Therapy CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Cell Therapy CDMO market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Cell Therapy CDMO market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Cell Therapy CDMO include Catalent, Lonza, Charles River, FUJIFILM Diosynth Biotechnologies, Exothera, Pharmaron, OBiO, AGC Biologics and Cytiva, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Cell Therapy CDMO market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Cell Therapy CDMO.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cell Therapy CDMO Market by Company
Catalent
Lonza
Charles River
FUJIFILM Diosynth Biotechnologies
Exothera
Pharmaron
OBiO
AGC Biologics
Cytiva
ThermoGenesis
eXmoor Pharma
Advanced Therapies
Catalent Biologics
Patheon Pharma Services
Sartorius
Genezen
The Discovery Labs
Cell Therapy CDMO Segment by Type
Autologous Cell Therapy CDMO
Allogeneic Cell Therapy CDMO
Viral Vector and Gene Editing CDMO
Cell Therapy CDMO Segment by Application
Commercial
Academic Research
Others
Cell Therapy CDMO Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cell Therapy CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cell Therapy CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cell Therapy CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Cell Therapy CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Autologous Cell Therapy CDMO
- Allogeneic Cell Therapy CDMO
- Viral Vector and Gene Editing CDMO
Applications
- Commercial
- Academic Research
- Others
Companies covered
- Catalent
- Lonza
- Charles River
- FUJIFILM Diosynth Biotechnologies
- Exothera
- Pharmaron
- OBiO
- AGC Biologics
- Cytiva
- ThermoGenesis
- eXmoor Pharma
- Advanced Therapies
- Catalent Biologics
- Patheon Pharma Services
- Sartorius
- Genezen
- The Discovery Labs
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Cell Therapy CDMO by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Autologous Cell Therapy CDMO
- 2.2.3 Allogeneic Cell Therapy CDMO
- 2.2.4 Viral Vector and Gene Editing CDMO
- 2.3 Cell Therapy CDMO by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Commercial
- 2.3.3 Academic Research
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Cell Therapy CDMO Breakdown Data by Type
- 3.1 Global Cell Therapy CDMO Historic Market Size by Type (2021-2026)
- 3.2 Global Cell Therapy CDMO Forecasted Market Size by Type (2027-2032)
4 Cell Therapy CDMO Breakdown Data by Application
- 4.1 Global Cell Therapy CDMO Historic Market Size by Application (2021-2026)
- 4.2 Global Cell Therapy CDMO Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Cell Therapy CDMO Market Perspective (2021-2032)
- 5.2 Global Cell Therapy CDMO Growth Trends by Region
- 5.2.1 Global Cell Therapy CDMO Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Cell Therapy CDMO Historic Market Size by Region (2021-2026)
- 5.2.3 Cell Therapy CDMO Forecasted Market Size by Region (2027-2032)
- 5.3 Cell Therapy CDMO Market Dynamics
- 5.3.1 Cell Therapy CDMO Industry Trends
- 5.3.2 Cell Therapy CDMO Market Drivers
- 5.3.3 Cell Therapy CDMO Market Challenges
- 5.3.4 Cell Therapy CDMO Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Cell Therapy CDMO Players by Revenue
- 6.1.1 Global Top Cell Therapy CDMO Players by Revenue (2021-2026)
- 6.1.2 Global Cell Therapy CDMO Revenue Market Share by Players (2021-2026)
- 6.2 Global Cell Therapy CDMO Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Cell Therapy CDMO Head Office and Area Served
- 6.4 Global Cell Therapy CDMO Players, Product Type & Application
- 6.5 Global Cell Therapy CDMO Manufacturers Established Date
- 6.6 Global Cell Therapy CDMO Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Cell Therapy CDMO Market Size (2021-2032)
- 7.2 North America Cell Therapy CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Cell Therapy CDMO Market Size by Country (2021-2026)
- 7.4 North America Cell Therapy CDMO Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Cell Therapy CDMO Market Size (2021-2032)
- 8.2 Europe Cell Therapy CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Cell Therapy CDMO Market Size by Country (2021-2026)
- 8.4 Europe Cell Therapy CDMO Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Cell Therapy CDMO Market Size (2021-2032)
- 9.2 Asia-Pacific Cell Therapy CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Cell Therapy CDMO Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Cell Therapy CDMO Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Cell Therapy CDMO Market Size (2021-2032)
- 10.2 South America Cell Therapy CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Cell Therapy CDMO Market Size by Country (2021-2026)
- 10.4 South America Cell Therapy CDMO Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Cell Therapy CDMO Market Size (2021-2032)
- 11.2 Middle East & Africa Cell Therapy CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Cell Therapy CDMO Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Cell Therapy CDMO Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Catalent
- 12.1.1 Catalent Company Information
- 12.1.2 Catalent Business Overview
- 12.1.3 Catalent Revenue in Cell Therapy CDMO Business (2021-2026)
- 12.1.4 Catalent Cell Therapy CDMO Product Portfolio
- 12.1.5 Catalent Recent Developments
- 12.2 Lonza
- 12.2.1 Lonza Company Information
- 12.2.2 Lonza Business Overview
- 12.2.3 Lonza Revenue in Cell Therapy CDMO Business (2021-2026)
- 12.2.4 Lonza Cell Therapy CDMO Product Portfolio
- 12.2.5 Lonza Recent Developments
- 12.3 Charles River
- 12.3.1 Charles River Company Information
- 12.3.2 Charles River Business Overview
- 12.3.3 Charles River Revenue in Cell Therapy CDMO Business (2021-2026)
- 12.3.4 Charles River Cell Therapy CDMO Product Portfolio
- 12.3.5 Charles River Recent Developments
- 12.4 FUJIFILM Diosynth Biotechnologies
- 12.4.1 FUJIFILM Diosynth Biotechnologies Company Information
- 12.4.2 FUJIFILM Diosynth Biotechnologies Business Overview
- 12.4.3 FUJIFILM Diosynth Biotechnologies Revenue in Cell Therapy CDMO Business (2021-2026)
- 12.4.4 FUJIFILM Diosynth Biotechnologies Cell Therapy CDMO Product Portfolio
- 12.4.5 FUJIFILM Diosynth Biotechnologies Recent Developments
- 12.5 Exothera
- 12.5.1 Exothera Company Information
- 12.5.2 Exothera Business Overview
- 12.5.3 Exothera Revenue in Cell Therapy CDMO Business (2021-2026)
- 12.5.4 Exothera Cell Therapy CDMO Product Portfolio
- 12.5.5 Exothera Recent Developments
- 12.6 Pharmaron
- 12.6.1 Pharmaron Company Information
- 12.6.2 Pharmaron Business Overview
- 12.6.3 Pharmaron Revenue in Cell Therapy CDMO Business (2021-2026)
- 12.6.4 Pharmaron Cell Therapy CDMO Product Portfolio
- 12.6.5 Pharmaron Recent Developments
- 12.7 OBiO
- 12.7.1 OBiO Company Information
- 12.7.2 OBiO Business Overview
- 12.7.3 OBiO Revenue in Cell Therapy CDMO Business (2021-2026)
- 12.7.4 OBiO Cell Therapy CDMO Product Portfolio
- 12.7.5 OBiO Recent Developments
- 12.8 AGC Biologics
- 12.8.1 AGC Biologics Company Information
- 12.8.2 AGC Biologics Business Overview
- 12.8.3 AGC Biologics Revenue in Cell Therapy CDMO Business (2021-2026)
- 12.8.4 AGC Biologics Cell Therapy CDMO Product Portfolio
- 12.8.5 AGC Biologics Recent Developments
- 12.9 Cytiva
- 12.9.1 Cytiva Company Information
- 12.9.2 Cytiva Business Overview
- 12.9.3 Cytiva Revenue in Cell Therapy CDMO Business (2021-2026)
- 12.9.4 Cytiva Cell Therapy CDMO Product Portfolio
- 12.9.5 Cytiva Recent Developments
- 12.10 ThermoGenesis
- 12.10.1 ThermoGenesis Company Information
- 12.10.2 ThermoGenesis Business Overview
- 12.10.3 ThermoGenesis Revenue in Cell Therapy CDMO Business (2021-2026)
- 12.10.4 ThermoGenesis Cell Therapy CDMO Product Portfolio
- 12.10.5 ThermoGenesis Recent Developments
- 12.11 eXmoor Pharma
- 12.11.1 eXmoor Pharma Company Information
- 12.11.2 eXmoor Pharma Business Overview
- 12.11.3 eXmoor Pharma Revenue in Cell Therapy CDMO Business (2021-2026)
- 12.11.4 eXmoor Pharma Cell Therapy CDMO Product Portfolio
- 12.11.5 eXmoor Pharma Recent Developments
- 12.12 Advanced Therapies
- 12.12.1 Advanced Therapies Company Information
- 12.12.2 Advanced Therapies Business Overview
- 12.12.3 Advanced Therapies Revenue in Cell Therapy CDMO Business (2021-2026)
- 12.12.4 Advanced Therapies Cell Therapy CDMO Product Portfolio
- 12.12.5 Advanced Therapies Recent Developments
- 12.13 Catalent Biologics
- 12.13.1 Catalent Biologics Company Information
- 12.13.2 Catalent Biologics Business Overview
- 12.13.3 Catalent Biologics Revenue in Cell Therapy CDMO Business (2021-2026)
- 12.13.4 Catalent Biologics Cell Therapy CDMO Product Portfolio
- 12.13.5 Catalent Biologics Recent Developments
- 12.14 Patheon Pharma Services
- 12.14.1 Patheon Pharma Services Company Information
- 12.14.2 Patheon Pharma Services Business Overview
- 12.14.3 Patheon Pharma Services Revenue in Cell Therapy CDMO Business (2021-2026)
- 12.14.4 Patheon Pharma Services Cell Therapy CDMO Product Portfolio
- 12.14.5 Patheon Pharma Services Recent Developments
- 12.15 Sartorius
- 12.15.1 Sartorius Company Information
- 12.15.2 Sartorius Business Overview
- 12.15.3 Sartorius Revenue in Cell Therapy CDMO Business (2021-2026)
- 12.15.4 Sartorius Cell Therapy CDMO Product Portfolio
- 12.15.5 Sartorius Recent Developments
- 12.16 Genezen
- 12.16.1 Genezen Company Information
- 12.16.2 Genezen Business Overview
- 12.16.3 Genezen Revenue in Cell Therapy CDMO Business (2021-2026)
- 12.16.4 Genezen Cell Therapy CDMO Product Portfolio
- 12.16.5 Genezen Recent Developments
- 12.17 The Discovery Labs
- 12.17.1 The Discovery Labs Company Information
- 12.17.2 The Discovery Labs Business Overview
- 12.17.3 The Discovery Labs Revenue in Cell Therapy CDMO Business (2021-2026)
- 12.17.4 The Discovery Labs Cell Therapy CDMO Product Portfolio
- 12.17.5 The Discovery Labs Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst